X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (33973) 33973
Book Review (7268) 7268
Publication (2886) 2886
Newspaper Article (798) 798
Newsletter (725) 725
Book Chapter (314) 314
Book / eBook (147) 147
Conference Proceeding (58) 58
Patent (57) 57
Magazine Article (26) 26
Dissertation (20) 20
Transcript (14) 14
Trade Publication Article (12) 12
Web Resource (7) 7
Data Set (5) 5
Reference (5) 5
Government Document (3) 3
Paper (2) 2
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (30020) 30020
humans (21081) 21081
animals (14848) 14848
pharmacology & pharmacy (11157) 11157
male (10659) 10659
enzymes (10388) 10388
enzyme inhibitors - pharmacology (7114) 7114
female (7003) 7003
rats (6079) 6079
pharmacokinetics (5085) 5085
mice (4965) 4965
metabolism (4502) 4502
adult (3918) 3918
biochemistry & molecular biology (3739) 3739
analysis (3566) 3566
cytochrome p-450 enzyme system - metabolism (3529) 3529
cancer (3490) 3490
drug interactions (3358) 3358
research (3317) 3317
middle aged (3277) 3277
dose-response relationship, drug (3249) 3249
oncology (3027) 3027
chemistry, medicinal (2969) 2969
physiological aspects (2918) 2918
toxicology (2790) 2790
in-vitro (2658) 2658
proteins (2632) 2632
enzyme inhibitors - pharmacokinetics (2484) 2484
inhibition (2347) 2347
health aspects (2316) 2316
pharmacology (2296) 2296
aged (2269) 2269
expression (2241) 2241
rats, sprague-dawley (2132) 2132
drugs (2108) 2108
enzyme inhibitors (2104) 2104
drug therapy (2089) 2089
enzyme inhibitors - therapeutic use (2063) 2063
kinetics (2005) 2005
care and treatment (2002) 2002
enzyme inhibitors - chemistry (1990) 1990
structure-activity relationship (1978) 1978
administration, oral (1917) 1917
liver (1902) 1902
metabolites (1864) 1864
medicine (1828) 1828
research article (1759) 1759
article (1753) 1753
cytochrome p-450 enzyme inhibitors (1746) 1746
apoptosis (1735) 1735
cell line, tumor (1698) 1698
pharmacology/toxicology (1688) 1688
cytochrome p-450 (1669) 1669
enzyme-linked immunosorbent assay (1629) 1629
rodents (1629) 1629
inhibitors (1591) 1591
cytochrome p450 (1557) 1557
cell biology (1533) 1533
medicine & public health (1520) 1520
abridged index medicus (1517) 1517
time factors (1496) 1496
multidisciplinary sciences (1495) 1495
neurosciences (1477) 1477
studies (1473) 1473
hypertension (1424) 1424
area under curve (1405) 1405
gene expression (1403) 1403
drug design (1393) 1393
antineoplastic agents - pharmacology (1383) 1383
molecular structure (1381) 1381
biotransformation (1368) 1368
microsomes, liver - metabolism (1356) 1356
rats, wistar (1356) 1356
cells (1350) 1350
toxicity (1346) 1346
in-vivo (1345) 1345
oxidative stress (1345) 1345
chemistry, organic (1342) 1342
microsomes, liver - enzymology (1342) 1342
cells, cultured (1320) 1320
in vitro techniques (1298) 1298
enzyme inhibitors - administration & dosage (1278) 1278
cytochrome p-450 cyp3a (1276) 1276
treatment outcome (1273) 1273
science (1251) 1251
biochemistry (1249) 1249
drug dosages (1241) 1241
activation (1203) 1203
clinical trials (1186) 1186
cytochrome p-450 enzyme system - genetics (1184) 1184
therapy (1176) 1176
inflammation (1163) 1163
biological availability (1151) 1151
chemotherapy (1140) 1140
genetic aspects (1140) 1140
kinases (1129) 1129
liver - metabolism (1126) 1126
models, molecular (1119) 1119
chromatography, high pressure liquid (1115) 1115
disease models, animal (1113) 1113
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (83) 83
Online Resources - Online (9) 9
Chemistry (A D Allen) - Stacks (8) 8
Collection Dvlpm't (Acquisitions) - Vendor file (7) 7
UofT at Mississauga - Stacks (7) 7
Collection Dvlpm't (Acquisitions) - Closed Orders (5) 5
Engineering & Comp. Sci. - Stacks (5) 5
UofT at Scarborough - Stacks (3) 3
UTL at Downsview - May be requested (2) 2
Chemistry (A D Allen) - Reference (1) 1
Collection Dvlpm't (Acquisitions) - Cancelled Order (1) 1
Engineering & Comp. Sci. - Reference (1) 1
Gerstein Science - Reference (1) 1
Mt Sinai Hospital - Pathology (1) 1
Online (1) 1
Online Resources - Pharmacy (1) 1
UofT at Mississauga - Reference (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (35605) 35605
German (126) 126
French (94) 94
Japanese (65) 65
Russian (58) 58
Spanish (55) 55
Chinese (20) 20
Italian (13) 13
Polish (12) 12
Dutch (7) 7
Danish (6) 6
Turkish (6) 6
Czech (5) 5
Hungarian (5) 5
Portuguese (4) 4
Swedish (4) 4
Finnish (3) 3
Norwegian (3) 3
Korean (2) 2
Slovak (2) 2
Croatian (1) 1
Romanian (1) 1
Serbian (1) 1
Slovenian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
2011, 1st ed., ISBN 9780470414118, xii, 302
"Few scientists have the knowledge to perform the studies that are necessary to discover and characterize enzyme inhibitors, despite the vested interest the... 
Enzymes | Enzyme inhibitors | Enzyme Activation | Pharmacokinetics | Drug Discovery | SCIENCE / Life Sciences / Molecular Biology | Enzyme activation
Book
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 01/2011, Volume 89, Issue 1, pp. 65 - 74
Four randomized, placebo‐controlled, crossover studies were conducted among 282 healthy subjects to investigate whether an interaction exists between... 
VARIABILITY | LANSOPRAZOLE | RABEPRAZOLE | THERAPY | CARDIOVASCULAR EVENTS | STENT PLACEMENT | PHARMACOLOGY & PHARMACY | OUTCOMES | ANTIPLATELET ACTION | PROTON-PUMP INHIBITORS | DRUG-INTERACTION | Proton Pump Inhibitors - pharmacology | Ticlopidine - pharmacology | Humans | Middle Aged | Half-Life | Male | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Enzyme Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - blood | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Omeprazole - pharmacology | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Enzyme Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Double-Blind Method | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Enzyme Inhibitors - pharmacology | Omeprazole - adverse effects | Ticlopidine - analogs & derivatives | Cross-Over Studies | Prodrugs - adverse effects | Prodrugs - pharmacokinetics | Cytochrome P-450 CYP2C19 | Platelet Activation - drug effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Prodrugs - pharmacology | Ticlopidine - blood | Omeprazole | Pantoprazole | Drug interactions | Analysis | Dosage and administration | Research | Patients | Health aspects | Index Medicus | Abridged Index Medicus
Journal Article
2009, 1st ed., Wiley series in drug discovery and development., ISBN 0470275006, xv, 1022
The book gives students and young researchers a resource on zinc enzymes, some of which were intensively studied for more than six decades and translated into... 
Drugs | Design | chemistry | Zinc enzymes | Carbonic Anhydrase Inhibitors | Inhibitors | Drug Design | pharmacokinetics | Zinc | Therapeutic use | Drug Delivery Systems | Medical / Pharmacology | Drug Discovery & Development
Book
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 03/2010, Volume 87, Issue 3, pp. 322 - 329
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 09/2013, Volume 76, Issue 3, pp. 455 - 466
AimsThe anticoagulant rivaroxaban is an oral, direct Factor Xa inhibitor for the management of thromboembolic disorders. Metabolism and excretion involve... 
cytochrome | glycoprotein | rivaroxaban | drug interactions | healthy subjects | 450 | P-glycoprotein | Rivaroxaban | Healthy subjects | Cytochrome P450 | Drug interactions | BAY-59-7939 | SAFETY | PREVENTION | PHARMACODYNAMICS | cytochrome P450 | PROTEASE INHIBITORS | IN-VITRO | FACTOR-XA INHIBITOR | ERYTHROMYCIN | PHARMACOLOGY & PHARMACY | LIVER-MICROSOMES | Anticoagulants - administration & dosage | Cytochrome P-450 Enzyme Inhibitors | Erythromycin - pharmacology | Ketoconazole - administration & dosage | Humans | Middle Aged | Cytochrome P-450 Enzyme System - metabolism | Midazolam - administration & dosage | Substrate Specificity | Metabolic Clearance Rate | Thiophenes - administration & dosage | Ketoconazole - pharmacology | Enzyme Inhibitors - administration & dosage | Young Adult | Drug Interactions | Enzyme Inhibitors - pharmacokinetics | Clarithromycin - pharmacokinetics | Clarithromycin - administration & dosage | Adult | Morpholines - administration & dosage | Enzyme Inhibitors - pharmacology | Ketoconazole - pharmacokinetics | Midazolam - pharmacokinetics | Cytochrome P-450 CYP3A - administration & dosage | Erythromycin - administration & dosage | ATP Binding Cassette Transporter, Subfamily B, Member 1 - antagonists & inhibitors | ATP Binding Cassette Transporter, Subfamily B, Member 1 - metabolism | Thiophenes - pharmacokinetics | Erythromycin - pharmacokinetics | Cytochrome P-450 CYP3A - metabolism | Adolescent | Anticoagulants - pharmacokinetics | Morpholines - pharmacokinetics | Clarithromycin - pharmacology | Midazolam - pharmacology | Ketoconazole | Protease inhibitors | Fluconazole | Proteases | Cytochrome P-450 | Dosage and administration | Anticoagulants (Medicine) | Erythromycin | Thromboembolism | Index Medicus
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 01/2006, Volume 79, Issue 1, pp. 103 - 113
Background and Objective: Many drugs, including proton pump inhibitors and certain antidepressants, are metabolized by the polymorphic cytochrome P450 (CYP)... 
Mephenytoin - pharmacokinetics | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Male | Ethiopia - epidemiology | Genetic Variation | Transfection | Enzyme Inhibitors - pharmacokinetics | Plasmids - genetics | Electrophoretic Mobility Shift Assay | Anticonvulsants - pharmacokinetics | Omeprazole - therapeutic use | Proton Pump Inhibitors | Gene Frequency | Genes, Reporter - genetics | Genotype | Omeprazole - pharmacokinetics | China - epidemiology | Reverse Transcriptase Polymerase Chain Reaction | Sweden - epidemiology | Enzyme Inhibitors - therapeutic use | Antidepressive Agents - therapeutic use | Phenotype | Animals | Cytochrome P-450 CYP2C19 | Mice | Mutation | Antidepressive Agents - pharmacokinetics | Mixed Function Oxygenases - genetics | Physiological aspects | Genetic research | Proton pump inhibitors | Cytochrome P-450 | Antidepressants, Tricyclic | Index Medicus | Abridged Index Medicus | Plasmids/genetics | Omeprazole/pharmacokinetics/therapeutic use | Antidepressive Agents/pharmacokinetics/therapeutic use | Ethiopia/epidemiology | Proton Pumps/antagonists & inhibitors | Mephenytoin/pharmacokinetics | Enzyme Inhibitors/pharmacokinetics/therapeutic use | China/epidemiology | Genes; Reporter/genetics | Mixed Function Oxygenases/genetics | Anticonvulsants/pharmacokinetics | Variation (Genetics) | Aryl Hydrocarbon Hydroxylases/genetics | Sweden/epidemiology
Journal Article
Blood, ISSN 0006-4971, 08/2017, Volume 130, Issue 6, pp. 722 - 731
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 3/2013, Volume 56, Issue 5, pp. 718 - 726
Background. Boceprevir represents a new treatment option for hepatitis C (HCV)—infected patients, including those with HCV/human immunodeficiency virus... 
HIV/AIDS | HIV | Protease inhibitors | Geometric mean | Memory interference | Drug interactions | Infections | Sample mean | Pharmacokinetics | Dosage | Hepacivirus | pharmacokinetics | darunavir | boceprevir | lopinavir | atazanavir | INFECTIOUS DISEASES | PLUS RIBAVIRIN | DRUG-INTERACTIONS | MICROBIOLOGY | IMMUNOLOGY | OATP1B1 | CYP3A | INTERFERON | COCKTAIL | CYTOCHROME-P450 ENZYMES | GENOTYPE 1 INFECTION | Hepacivirus - drug effects | Darunavir | Proline - analogs & derivatives | Area Under Curve | HIV-1 - drug effects | Protease Inhibitors - pharmacokinetics | Humans | Middle Aged | Oligopeptides - pharmacokinetics | Pyridines - pharmacokinetics | Male | Sulfonamides - pharmacokinetics | Lopinavir - pharmacokinetics | Proline - pharmacokinetics | Dose-Response Relationship, Drug | Young Adult | Drug Interactions | Ritonavir - pharmacokinetics | HIV Protease Inhibitors - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Atazanavir Sulfate | Adult | Female | Boceprevir | Pharmacology, Experimental | Atazanavir | Lopinavir | Dosage and administration | Drug therapy, Combination | Hepatitis C virus | Drug therapy | Health aspects | Clinical trials | Hepatitis | Prescription drugs | Pharmacology | Human immunodeficiency virus--HIV | Index Medicus | All-terrain vehicles | Antiviral agents | Side effects | Ritonavir | Drug interaction | Proteinase inhibitors | Hepatitis C
Journal Article
Journal Article
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 01/2013, Volume 62, Issue 1, pp. 21 - 27
Journal Article